Evidence map›Paper›PMID 28376154›Full record

ArticleJournal of the National Cancer Institute2017

Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.

Ahmedin Jemal, Elizabeth M Ward, Christopher J Johnson, Kathleen A Cronin, Jiemin Ma, Blythe Ryerson, Angela Mariotto, Andrew J Lake, Reda Wilson, Recinda L Sherman and 6 more

3 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 853 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
853citing papers in PubMed, 4 pooled it
74.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03255135 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes.

TypeinterventionalSponsorHospital de Transplante Doutor Euryclides de Jesus ZerbiniRan2018 to 2019Enrolled130ConditionsProstate Cancer, Prostate Adenocarcinoma, Transrectal High Intensity Focused UltrasoundArmsHIFU
NCT03289221 nacompletednot on this mapstarted 2018, after this paper: background citation

Effects of High-Intensity Focused Ultrasound (HIFU) Treatment on Fecal Continence and Anorretal Fisiology

TypeinterventionalSponsorHospital de Transplante Doutor Euryclides de Jesus ZerbiniRan2018 to 2019Enrolled30ConditionsAnal Continence After High-Intensity Focused Ultrasound (HIFU) TreatmentArmsAnal Manometry
NCT06207864 narecruitingnot on this mapstarted 2022, after this paper: background citation

Participant Engagement - Cancer Genome Sequencing (PE-CGS) Research Center: Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

TypeinterventionalSponsorNew Mexico Cancer Research AllianceRan2022 to 2030Enrolled1,001ConditionsMalignant NeoplasmArmsBiospecimen Collection, Return of Results, Survey Administration
3 · Its place in the literature

Who cites it

853 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,572 citations in OpenAlex.

  1. Pooled it
  2. A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Disentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Article

793 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Ahmedin JemalSurveillance and Health Services Research, American Cancer Society, Atlanta, GA, USA.
Elizabeth M WardIntramural Research, American Cancer Society, Atlanta, GA, USA.
Christopher J JohnsonCancer Data Registry of Idaho, Boise, ID, USA.
Kathleen A CroninDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Jiemin MaSurveillance and Health Services Research, American Cancer Society, Atlanta, GA, USA.
Blythe RyersonDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Angela MariottoDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Andrew J LakeInformation Management Services, Inc., Rockville, MD, USA.
Reda WilsonDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Recinda L ShermanNorth American Association of Central Cancer Registries, Springfield, IL, USA.
Robert N AndersonNational Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD, USA.
S Jane HenleyDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Betsy A KohlerNorth American Association of Central Cancer Registries, Springfield, IL, USA.
Lynne PenberthyDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Eric J FeuerDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Hannah K WeirDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
National Cancer Institute · USAmerican Cancer Society · USCenters for Disease Control and Prevention · USNational Center for Chronic Disease Prevention and Health Promotion · USNorth American Association of Central Cancer Registries · USInformation Management Services · USNational Center for Health Statistics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States. This Annual Report highlights survival rates. Data were from the CDC- and NCI-funded population-based cancer registry programs and compiled by NAACCR. Trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types by sex were estimated by joinpoint analysis and expressed as annual percent change. We used relative survival ratios and adjusted relative risk of death after a diagnosis of cancer (hazard ratios [HRs]) using Cox regression model to examine changes or differences in survival over time and by sociodemographic factors. Results: Overall cancer death rates from 2010 to 2014 decreased by 1.8% (95% confidence interval [CI] = -1.8 to -1.8) per year in men, by 1.4% (95% CI = -1.4 to -1.3) per year in women, and by 1.6% (95% CI = -2.0 to -1.3) per year in children. Death rates decreased for 11 of the 16 most common cancer types in men and for 13 of the 18 most common cancer types in women, including lung, colorectal, female breast, and prostate, whereas death rates increased for liver (men and women), pancreas (men), brain (men), and uterine cancers. In contrast, overall incidence rates from 2009 to 2013 decreased by 2.3% (95% CI = -3.1 to -1.4) per year in men but stabilized in women. For several but not all cancer types, survival statistically significantly improved over time for both early and late-stage diseases. Between 1975 and 1977, and 2006 and 2012, for example, five-year relative survival for distant-stage disease statistically significantly increased from 18.7% (95% CI = 16.9% to 20.6%) to 33.6% (95% CI = 32.2% to 35.0%) for female breast cancer but not for liver cancer (from 1.1%, 95% CI = 0.3% to 2.9%, to 2.3%, 95% CI = 1.6% to 3.2%). Survival varied by race/ethnicity and state. For example, the adjusted relative risk of death for all cancers combined was 33% (HR = 1.33, 95% CI = 1.32 to 1.34) higher in non-Hispanic blacks and 51% (HR = 1.51, 95% CI = 1.46 to 1.56) higher in non-Hispanic American Indian/Alaska Native compared with non-Hispanic whites. Conclusions: Cancer death rates continue to decrease in the United States. However, progress in reducing death rates and improving survival is limited for several cancer types, underscoring the need for intensified efforts to discover new strategies for prevention, early detection, and treatment and to apply proven preventive measures broadly and equitably.

Indexed as

American Cancer SocietyCenters for Disease Control and Prevention, U.S.Cross-Sectional StudiesFemaleHumansIncidenceMaleNeoplasmsProportional Hazards ModelsRegistriesSEER ProgramSex FactorsSurvival RateUnited States

Identifiers

PMID28376154
PMCPMC5409140
OpenAlexW2601868035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.